Who's best placed to survive the credit crunch? This management report analyses the structure, performance, R&D and products of 58 leading cardiovascular device manufacturers.
Additional Information
The recession has caused many companies to reconsider their corporate strategy and research outlook. With the financial crisis, expansion through acquisition has no longer been possible and companies have been forced to plan for organic growth based on product efficiency, innovation, service and price.
Against a fragile and recovering economic backdrop, the key players in the cardiovascular field are now emerging as leaner, stronger and more focused entities that are exploring opportunities in biologics and other development areas. M&A's may grab the headlines but it is product portfolios that are really beginning to excite and attract observers.
Now in its fourth year of publication, the latest 2009 release of Who's Developing What in Cardiovascular Devices? provides the ideal opportunity to review the progress, and monitor the prospects, of both emerging and established industry participants.
(0 items)
